Aivlosin will be used in pheasants for the treatment of respiratory disease caused by Mycoplasma gallisepticum, one of the most economically important diseases of farmed pheasants.
EAH said there was an “unmet demand” for this kind of product in the market, with Aivlosin being the first authorised product for the treatment of this condition.
The product will be marketed directly to specialist poultry veterinarians in the UK, which, along with France, accounts for the majority of intensively reared pheasants in the EU with 30 million birds reared in these two countries annually.
Aivlosin is EAH’s flagship product, targeting a wide range of diseases spanning from enzootic pneumonia to swine dysentery and accounting for more than half of its sales.
The drug has also been approved for use pigs and poultry in Europe, South Africa, Japan, Asia and South America with EAH expecting it to receive approvals for use in pigs in the United States.
.jpg)
